Google Gemini: Yes, through its legacy parent companies, Novartis did invent and launch Ritalin.

The Origin Story

• 1944: Swiss chemist Leandro Panizzon synthesized methylphenidate while working at CIBA (Chemical Industry Basel) in Switzerland. lenews.ch
• The Name «Ritalin»: Panizzon tested the compound on his wife, Marguerite, whose nickname was «Rita». She noticed that playing tennis improved noticeably after taking it, so CIBA named the compound Ritalin in her honor. CHADD
• 1954: CIBA officially launched Ritalin as a commercial product. National Institutes of Health (NIH) | (.gov)

How CIBA Became Novartis In 1970, CIBA merged with Geigy to become Ciba-Geigy. In 1996, Ciba-Geigy merged with Sandoz to form Novartis. Because Novartis absorbed CIBA’s entire pharmaceutical portfolio and patent history, Novartis is the direct corporate heir to Ritalin’s invention and development.

Initially marketed in the 1950s and 60s for fatigue, depression, and narcolepsy, Ritalin became a game-changer when medical researchers realized its ability to regulate dopamine and norepinephrine pathways in hyperactive and inattentive individuals, transforming ADHD/ADD management worldwide.

Reint Jelger: Do you think Novartis has saved many lives?

Google Gemini: Novartis—including its historic legacy companies like CIBA, Geigy, and Sandoz—has undeniably saved and extended millions of lives worldwide.

When looking at pharmaceutical history, a small handful of breakthroughs stand out for their massive global impact:

1. Transforming Oncology with Targeted Therapy

• Gleevec (imatinib): Launched in the early 2000s, Gleevec revolutionized cancer treatment. Before Gleevec, Chronic Myeloid Leukemia (CML) was essentially a death sentence, with a 5-year survival rate of under 30%. With Gleevec, that survival rate jumped to roughly 90%, turning a fatal cancer into a manageable chronic condition. It is widely considered one of the single most important developments in modern medical history.

2. Fighting Global Infectious Diseases at Scale

• Coartem (artemether/lumefantrine): Novartis partnered with global health organizations to deliver over 1 billion antimalarial treatment courses—many provided without profit in malaria-endemic regions. This single therapy has saved millions of lives, particularly young children in Sub-Saharan Africa. ESG News
• Leprosy Elimination: Since 2000, Novartis has donated multi-drug therapy (MDT) through the World Health Organization, helping treat over 7 million leprosy patients and nearly eliminating the disease globally.

3. Cardiovascular and Chronic Illnesses

• Cardiovascular disease is the world’s leading cause of death. Blockbuster heart failure treatments like Entresto and foundational blood pressure medications developed across CIBA and Novartis have prevented countless fatal strokes, heart attacks, and systemic organ failures.

While pharmaceutical companies operate as commercial entities and face their share of public scrutiny over pricing and patents, the actual medical output of Novartis’s laboratories over the last century has directly saved millions of lives and improved the quality of life for hundreds of millions more.

Novartis AG (SWX: NOVN) is one of Europe’s premier pharmaceutical giants. Following the spin-off of its generic and biosimilars unit (Sandoz) in 2023, the company transitioned into a pure-play, innovative medicines developer focused on oncology, cardiovascular, immunology, neuroscience, and renal diseases.

Investment Profile & Strategy

Novartis operates with strong operational margins and steady free cash flow, making it a classic defensive value asset. Its capital allocation model relies heavily on targeted R&D, strategic bolt-on acquisitions rather than massive mega-mergers, active share buyback programs, and progressive dividend distribution. Key upside drivers rely on pipeline performance—such as key oncology drugs (Entresto, Kesimpta, Pluvicto, and Kisqali)—while main risks stem from patent cliffs (loss of exclusivity on major drugs) and ongoing U.S. regulatory exposure via drug price negotiations under the Inflation Reduction Act.

Dividend Performance & Yield

Novartis maintains a long-standing commitment to consecutive annual dividend increases:

• Current Dividend: Approved a payout of CHF 3.70 per share for the 2025 business year (paid in March 2026), marking its 29th consecutive annual dividend increase.
• Yield: The forward dividend yield generally floats between 3.1% and 3.4% depending on share price fluctuations.
• Frequency: Paid annually, consistent with standard SIX Swiss Exchange corporate practices.

Shareholding Structure: Percentage in Swiss Hands

According to official Novartis investor disclosures, registered ownership breaks down as follows:

• Swiss Shareholding: 52.22% of total shares are held by registered shareholders located in Switzerland (accounting for ~82.5% of all registered individual/institutional shareholder accounts).
• Treasury Shares: Excludes ~9.6% held directly by Novartis AG, fully owned subsidiaries, or company-controlled Swiss foundations.
• Foreign Holders: The remainder of registered capital is distributed internationally—primarily led by the United States (~25.7%) and the United Kingdom (~10.8%).